| Followers | 202 |
| Posts | 25627 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Wednesday, November 24, 2021 3:29:05 PM
The trial itself may have been the reason for slowness, and the expected change to OS as the primary measure, as well as changes at the FDA that would make completing the trial more easy to be fully approvable.
If you know a policy is about to change that will make an approval more certain, why would you rush to get permission on the legacy basis not intended for trials like yours and which therefore might not be the correct decision?
You have heard that old story of the tortoise and the hare? It actually quite frequently has very real implications. That’s why it is such an amusing and often retold story.
Also, if they are not actually being secret and everyone knows already, then why complain if you already know everything. I do not think that, but you’re complaining they are quiet but nothing is a secret. I don’t really even get that last part. How is that even possible and how is it then that they are being quiet? Do you have inside info? I don’t. I do not perceive that others do either.
If you know a policy is about to change that will make an approval more certain, why would you rush to get permission on the legacy basis not intended for trials like yours and which therefore might not be the correct decision?
You have heard that old story of the tortoise and the hare? It actually quite frequently has very real implications. That’s why it is such an amusing and often retold story.
Also, if they are not actually being secret and everyone knows already, then why complain if you already know everything. I do not think that, but you’re complaining they are quiet but nothing is a secret. I don’t really even get that last part. How is that even possible and how is it then that they are being quiet? Do you have inside info? I don’t. I do not perceive that others do either.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
